Q-omics provides the consensus-scored GALR3 profile across patient tissues and cancer cell-line models. GALR3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GALR3 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, GALR3 RNA expression shows 12,542 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, UCEC, and TGCT as cancer lineages where GALR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALR3 survival associations across molecular data types. GALR3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALR3 RNA expression–survival associations across cancer types. High GALR3 expression shows unfavorable associations in ACC, COAD and KIRP, but favorable associations in SCLC, LGG and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GALR3 RNA expression.
This table summarizes GALR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for GALR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALR3 shows lower tumor expression in THCA and higher tumor expression in UCEC, LIHC, LUSC, READ and LUAD. The UCEC box plot shows higher GALR3 RNA expression in tumor versus normal tissue (log2 FC = +0.342, t-test p = .005).
This table shows molecular features associated with GALR3 in patient tissues and cancer cell lines. In patient samples, GALR3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GALR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
